- Home
- FISV vs RVMD Comparison
FISV vs RVMD Comparison
Compare FISV & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FISV | RVMD |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | 38000 | 883 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 30.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FISV | RVMD |
|---|---|---|
| Price | $49.17 | $158.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 19 |
| Target Price | ★ $146.17 | $140.84 |
| AVG Volume (30 Days) | ★ 7.2M | 2.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.94 | $533.02 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.37 | $34.00 |
| 52 Week High | $70.41 | $166.50 |
Technical Indicators
Market Signals| Indicator | FISV | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 57.99 |
| Support Level | N/A | $141.22 |
| Resistance Level | $64.56 | $166.50 |
| Average True Range (ATR) | 2.19 | 6.52 |
| MACD | -0.60 | -0.22 |
| Stochastic Oscillator | 12.30 | 66.64 |
Price Performance
Historical ComparisonAbout FISV Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.